Eagle Asset Management Inc Acadia Pharmaceuticals Inc Transaction History

Eagle Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$36.42 - $57.0 $2.18 Million - $3.42 Million	-59,931 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$39.26 - $52.73 $37.6 Million - $50.5 Million	-957,556 Reduced 94.11%	59,931 $2.89 Million
Q1 2020 May 11, 2020	BUY	$31.65 - $46.87 $382,363 - $566,236	12,081 Added 1.2%	1,017,487 $43 Million
Q4 2019 Feb 07, 2020	SELL	$36.21 - $51.4 $190,355 - $270,209	-5,257 Reduced 0.52%	1,005,406 $43 Million
Q3 2019 Nov 04, 2019	BUY	$22.22 - $44.01 $234,309 - $464,085	10,545 Added 1.05%	1,010,663 $36.4 Million
Q2 2019 Aug 05, 2019	BUY	$23.32 - $28.12 $23.3 Million - $28.1 Million	1,000,118 New	1,000,118 $26.7 Million

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.62B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.